Non-fucosylated Anti-Human CD19 (Blinatumomab) Therapeutic Antibody (CAT#: BioBet-010ZP) Datasheet

CD19

CD19 molecule

Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.

CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Plasma membrane

Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.

Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).

As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signaling pathway activation and trigger b-cell response to antigen (PubMed: 2463100, PubMed: 1373518, PubMed: 16672701). Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Not needed in the early steps of bone marrow B cell differentiation (PubMed:9317126). Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges (PubMed: 2463100, PubMed: 1373518). Requires normal levels of serum immunoglobulins, and high-affinity antibodies produced upon antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).

Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody

Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Phosphorylated on tyrosine residues by LYN.

Protein Based Therapies
Monoclonal antibody (mAb)

scFv, kappa

Blinatumomab

Mouse

Human

Blinatumomab is a bispecific T-cell conjugate (BiTE) that selectively acts and guides the human immune system against tumor cells. In 2014, the product was approved by the US Food and Drug Administration under the accelerated approval program and used as a second-line treatment for Philadelphia chromosome-negative relapse or refractory acute lymphoblastic leukemia. Blinatumomab specifically targets the CD19 antigen present on B cells.

Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia

AMG103, MT103

Blinatumomab is a CD19-specific bispecific CD3 T cell adaptor that can simultaneously target CD19 expressed on the surface of cells of the B lineage and CD3 expressed on the surface of T cells. It activates endogenous T cells by linking CD3 in the T cell receptor (TCR) complex with CD19 on benign and malignant B cells, mediating the release of inflammatory cytokines and the proliferation of T cells, which leads to CD19 + Redirected lysis of cells.

Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia